Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for mifamurtide

  1. Mifamurtide for the treatment of osteosarcoma (TA235)

    Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.

    Technology appraisal guidance
    Published
    26 October 2011
    View recommendations

    Sections for TA235

  2. Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical of UK clinical practice would be useful to determine the size of the effect of mifamurtide.

    Question Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical of UK clinical...

    Research recommendation
    Published
    9 June 2015

  3. Further collection of quality of life data from people who are cured and who have experience of amputation and chemotherapy are also needed. Additional data on the health effects on parents, siblings and others with life-threatening illness would also be of value.

    None. Source guidance details Comes from guidance Mifamurtide for the treatment of osteosarcoma Number TA235 Date issued

    Research recommendation
    Published
    9 June 2015